Abstract: The Protocolised Management in Sepsis (ProMISe) trial (April 2 issue) completes a trio of studies that question the further application of early, goal-directed therapy (EGDT) as suggested by Rivers et al. In particular, these trials consistently show no survival benefit with regard to the mandated use of central venous oxygen saturation (ScvO 2 ) monitoring. However, it remains questionable whether the results of the three trials support this claim. According to the EGDT protocol, an ScvO 2 value of less than 70% is a trigger for hemodynamic intervention. Unlike in the study by Rivers et al., the reported mean values at baseline in all three trials do not require any intervention. Whether the reported survival benefit in the study by Rivers et al. is based on the treatment of patients with initially extremely low ScvO 2 values and determines the targeted patient population that benefits from EGDT remains, therefore, unanswered. Pope et al. reported increased mortality when ScvO 2 values were initially low (<70%) or high (>80%). Unless subgroup analyses and further studies that focus on these high-risk patients do not rule out a survival benefit, the final conclusion of the three trials cannot be supported.
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To the Editor: The Protocolised Management in Sepsis (ProMISe) trial (April 2 issue) 1 completes a trio of studies [1] [2] [3] that question the further application of early, goal-directed therapy (EGDT) as suggested by Rivers et al. 4 In particular, these trials consistently show no survival benefit with regard to the mandated use of central venous oxygen saturation (ScvO 2 ) monitoring. However, it remains questionable whether the results of the three trials support this claim. According to the EGDT protocol, an ScvO 2 value of less than 70% is a trigger for hemodynamic intervention. Unlike in the study by Rivers et al., the reported mean values at baseline in all three trials do not require any intervention. Whether the reported survival benefit in the study by Rivers et al. is based on the treatment of patients with initially extremely low ScvO 2 values and determines the targeted patient population that benefits from EGDT remains, therefore, unanswered. Pope et al. 5 reported increased mortality when ScvO 2 values were initially low (<70%) or high (>80%). Unless subgroup analyses and further studies that focus on these high-risk patients do not rule out a survival benefit, the final conclusion of the three trials cannot be supported. 
DOI: 10.1056/NEJMc1506514
To the Editor: The ProMISe trial investigators report that EGDT did not reduce 90-day mortality among patients with early septic shock. Fluid therapy is crucial in EGDT. By 72 hours, approximately 40% of the study patients had received a median of 1.0 liter of intravenous colloids, and 98% of the patients had received a median of 4.9 liters of intravenous crystalloids (Table S7 in No potential conflict of interest relevant to this letter was reported. 
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To the Editor: The ProMISe trial, the Australasian Resuscitation in Sepsis Evaluation (ARISE) trial, and the Protocolized Care for Early Septic Shock (ProCESS) trial suggest no additional benefit from hemodynamic management with strict EGDT, characterizing EGDT only as a hemodynamic study. In addition to hemodynamic monitoring from the EGDT component, the Surviving Sepsis Campaign (SSC) guidelines 1 include early detection of high-risk patients with the use of the criteria of the systemic inflammatory response syndrome, the shock index (ratio of heart rate to systolic blood pressure), and measurement of serum lactate levels. EGDT has played a central role in the development of current tenets of shock management. In the triad of randomized, controlled trials, each component of EGDT was applied in all groups except monitoring of central venous pressure and ScvO 2 , and they were provided in more than 50% of the participants in the usual-care groups. Mortality decreased in both control and intervention groups by more than 50% -a greater degree than in previous trials. These results strongly support the pivotal role of the SSC guidelines that include EGDT. [1] [2] [3] Although these trials reveal that monitoring of central venous pressure is not mandatory, they show no harm in EGDT and certainly do not suggest that other aspects of the guidelines be called into question. We are concerned that the conclusions promulgated by the triad of trials will be misinterpreted and will cast doubt on the importance of SSC protocols for sepsis detection and treatment. ScvO 2 (because ScvO 2 data were not available for the usual-care groups), showed no evidence of benefit.
We agree with Priebe that administration of intravenous isotonic saline solutions can cause hyperchloremia and acidosis. In the ProMISe trial, although we did not record the type of crystalloid administered or the serum chloride level, the volume of crystalloid administered by 72 hours after randomization was similar in the EGDT and usual-care groups, and it is likely that, on average, the fluids used were the same in the two groups. With respect to red-cell transfusions, the evidence base is conflicting, with more recent data 4,5 indicating no evidence of harm caused by transfusions.
Manaktala and Claypool are concerned about misinterpretation of the results of the ProCESS, ARISE, and ProMISe trials. With interpretation in mind, we stated in the Conclusions section of the abstract of our article that "in patients with septic shock who were identified early and received intravenous antibiotics and adequate fluid resuscitation, hemodynamic management according to a strict EGDT protocol did not lead to an improvement in outcome."
